Stockscreener 앱 받기
7.69
1.44%
0.07
전일 마감가:
$7.62
열려 있는:
$7.57
하루 거래량:
121.17K
Relative Volume:
0.42
시가총액:
$248.34M
수익:
-
순이익/손실:
$-47.20M
주가수익비율:
-4.9128
EPS:
-1.5653
순현금흐름:
$-43.65M
1주 성능:
+4.04%
1개월 성능:
-2.03%
6개월 성능:
-67.64%
1년 성능:
+0.00%
1일 변동 폭
$7.20
$7.86
1주일 범위
$6.94
$7.86
52주 변동 폭
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
11711 N. MERIDIAN STREET, CARMEL
MBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
7.68 | 248.34M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.21 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.57 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.64 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | JP Morgan | Overweight |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Stifel | Buy |
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
5,593 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Corebridge Financial Inc. - Defense World
25,000 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Norges Bank - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Receives $37.40 Consensus Price Target from Brokerages - Defense World
MBX Biosciences initiated at Market Outperform by Citizens - MSN
Director Makes Bold Move with Major MBX Biosciences Stock Purchase - TipRanks
JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation - Nasdaq
MBX Biosciences: Innovative PEP Platform and Promising Pipeline Drive Buy Rating - TipRanks
MBX Bio stock initiated at Market Outperform by Citizens (MBX) - Seeking Alpha
MBX Biosciences director Pescovitz buys $45,311 in stock By Investing.com - Investing.com Canada
MBX Biosciences director Pescovitz buys $45,311 in stock - Investing.com
MBX Biosciences initiated with an Outperform at Citizens JMP - TipRanks
MBX Biosciences adds biotech veteran to board By Investing.com - Investing.com South Africa
MBX Biosciences adds biotech veteran to board - Investing.com Australia
MBX Biosciences Appoints Steve Hoerter to Board - TipRanks
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors - GlobeNewswire
From $2.4B Exit to Next Biotech Success: Pharma Veteran Steve Hoerter Strengthens MBX Board - Stock Titan
Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Bank of New York Mellon Corp Buys Shares of 23,914 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
MBX Biosciences Unveils Next-Gen Peptide Therapies: CEO Presentation at Major Healthcare Conference - Stock Titan
MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus
MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts - TipRanks
MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN
MBX Biosciences stock jumps 5% on clinical trial progress By Investing.com - Investing.com Australia
MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - marketscreener.com
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance
Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Rhumbline Advisers Purchases New Holdings in MBX Biosciences, Inc. (NYSE:MBX) - The AM Reporter
MBX Biosciences Announces Additions to Leadership Team - GlobeNewswire
MBX Biosciences strengthens leadership team with new SVPs By Investing.com - Investing.com Canada
MBX Biosciences Announces Additions To Leadership Team -March 05, 2025 at 08:53 am EST - Marketscreener.com
MBX Biosciences strengthens leadership team with new SVPs - Investing.com India
MBX Biosciences, Inc.’s Lock-Up Period Will Expire on March 12th (NYSE:MBX) - Defense World
MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of Canvuparatide For HP - Nasdaq
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - The Manila Times
MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109 - TipRanks
Can This Overenrolled Clinical Trial Transform Hypoparathyroidism Treatment? - StockTitan
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of Stock - MarketBeat
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Purchases 143,170 Shares of Stock - MarketBeat
Major Stakeholders Double Down on MBX Biosciences with Substantial Stock Purchases! - TipRanks
Mbx biosciences director Carl Gordon purchases over $2 million in stock - Investing.com Nigeria
Mbx biosciences director Carl Gordon purchases over $2 million in stock By Investing.com - Investing.com South Africa
OrbiMed Advisors makes $2 million investment in MBX Biosciences By Investing.com - Investing.com Nigeria
MBX Biosciences to Participate in March Investor Conferences - GlobeNewswire
Mbx Biosciences Inc (MBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.11%
자본화:
|
볼륨(24시간):